The CAR-T landscape is dominated by blood cancers, which account for more than half of all CAR-Ts in the active pipeline and ...

TiCARos’ mission is to create a paradigm shift in the CAR-T therapeutics landscape that could achieve a complete cure for both intractable hematologic malignancies and advanced solid tumors ...

What challenges does Allogene face in the competitive CAR T landscape? Allogene operates in a highly competitive field, with several companies developing both autologous and allogeneic CAR T ...

The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market. Ben Hargreaves finds that the early leaders, Gilead and Novartis ...

Bristol Myers Squibb remains the dominant player in the CAR-T landscape with two already marketed products—Abecma (idecabtagene vicleucel) for multiple myeloma and Breyanzi (lisocabtagene ...

What challenges does Adicet Bio face in the competitive CAR-T landscape? Adicet Bio operates in a highly competitive field, with numerous companies developing CAR-T and other cell therapies for ...

With the continuing evolution of the CAR-T landscape, Research Partnership speaks to payers across Europe to investigate the market access and commercialisation potential for manufacturers of ...

Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy. It uses a patient’s own immune system to fight certain blood cancers. Normal T cells can “hook” onto cancer cells and kill them, but ...

What challenges does Allogene face in the competitive CAR T landscape? Allogene operates in a highly competitive field, with several companies developing both autologous and allogeneic CAR T therapies ...